Longeveron enters $10.7M ATM equity offering with H.C. Wainwright

Longeveron Inc.

Up to $10.7M of Class A common stock may be sold at market prices through agent Wainwright.
Commission 3.0% of gross proceeds; company reimburses up to $100k legal fees plus periodic diligence fees.
Net proceeds to fund clinical development of laromestrocel for HLHS, Alzheimer's, and pediatric DCM.
No minimum sales obligation; company or Wainwright may suspend the offering at any time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.